Gilead Sciences (GILD) FCF Payout Ratio (2009 - 2026)
Gilead Sciences (GILD) reported FCF Payout Ratio of 0.43 for Q1 2026, down 29.45% on a YoY basis from 0.61 in Q1 2025, and up 34.59% quarter-over-quarter from 0.32 in Q4 2025.
Gilead Sciences (GILD) FCF Payout Ratio (2009 - 2026) Analysis & Trends
Gilead Sciences has reported FCF Payout Ratio for 13 years, with the latest figure at 0.43 in Q1 2026.
- For the quarter ending Q1 2026, FCF Payout Ratio fell 29.45% year-over-year to 0.43; the trailing twelve-month figure through Mar 2026 stood at 0.39 (down 1.47% YoY), and the FY2025 full-year result was 0.42, up 11.34% from the prior year.
- FCF Payout Ratio for Q1 2026 stood at 0.43, up from 0.32 in the prior quarter.
- The five-year high for FCF Payout Ratio was 1.38 in Q2 2025, with the low at 0.23 in Q3 2024.
- Historically, FCF Payout Ratio has averaged 0.52 across 5 years, with a median of 0.46 in 2024.
- The largest YoY upside for FCF Payout Ratio was 88.65% in 2024 against a maximum downside of 59.83% in 2024.
- Gilead Sciences' FCF Payout Ratio stood at 0.39 in 2022, then gained by 23.94% to 0.48 in 2023, then dropped by 28.86% to 0.34 in 2024, then decreased by 7.46% to 0.32 in 2025, then jumped by 34.59% to 0.43 in 2026.
- The last three FCF Payout Ratio figures came in at 0.43 (Q1 2026), 0.32 (Q4 2025), and 0.25 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -0.41 |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.51 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.87 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.72 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.92 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.43 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 1.12 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.69 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.43 |
| Dec 31, 2025 | 0.32 |
| Sep 30, 2025 | 0.25 |
| Jun 30, 2025 | 1.38 |
| Mar 31, 2025 | 0.61 |
| Dec 31, 2024 | 0.34 |
| Sep 30, 2024 | 0.23 |
| Jun 30, 2024 | 0.82 |
| Mar 31, 2024 | 0.46 |
| Dec 31, 2023 | 0.48 |
| Sep 30, 2023 | 0.58 |
| Jun 30, 2023 | 0.43 |
| Mar 31, 2023 | 0.59 |
| Dec 31, 2022 | 0.39 |
| Sep 30, 2022 | 0.34 |
| Jun 30, 2022 | 0.56 |
| Mar 31, 2022 | 0.59 |
| Dec 31, 2021 | 0.29 |
| Sep 30, 2021 | 0.29 |
| Jun 30, 2021 | 0.41 |